Top Markets
Coin of the day
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Rang in aandelen #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Aandeelprijs
$1.11
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$100.55M
Verandering (1 dag)
-7.69%
Verandering (1 jaar)
-7.17%
Land
TW
Handel Senhwa Biosciences, Inc. (6492)

Categorie

Prijs 6492 met de marktkapitalisatie van B
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
6492
$1.11
Marktkapitalisatie van Senhwa Biosciences, Inc.(6492)
Marktkapitalisatie: $100.55M
Vanaf August 2026 heeft Senhwa Biosciences, Inc. een marktkapitalisatie van $100.55M. Dit maakt Senhwa Biosciences, Inc. volgens onze gegevens het 21774th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Senhwa Biosciences, Inc. van 2014 tot 2026
6492 vergeleken met de top 5 populairste stocks
Prijs voor 6492 Aandeel B Marktkapitalisatie van B uitslagen
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$57,355.39 $100.55M
$5.211T +5,182,899.16%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$50,040.67 $100.55M
$4.547T +4,521,894.34%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$45,811.46 $100.55M
$4.162T +4,139,716.21%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$39,541.61 $100.55M
$3.593T +3,573,132.23%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$30,737.65 $100.55M
$2.793T +2,777,550.53%